Organoids

#Advertorial #HUB Organoids #KRAS #Organoids

KRAS is no longer undruggable. Is your preclinical model ready?

In this paid-for advertorial for the Fall 2026 issue of DDW, HUB Organoids shares insight on KRAS inhibitor development.  KRAS inhibitor development has moved past single-allele chemistry into pan-RAS and combination strategies. HUB Organoids' patient-derived organoid platform gives your programme the resistance data, allele breadth, and combination evidence next-generation KRASi… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Drug discovery #Infectious diseases #Lab automation #Organoids #UK

New robotic AI lab opens in Liverpool to help fight infectious diseases  

The UK’s first high-security robotic AI laboratory designed to accelerate the discovery of drugs and vaccines for infectious diseases has opened in Liverpool.   The £20 million Liverpool Accelerate Laboratory has been developed through the Infection Innovation Consortium: iiCON, which advances pioneering infection R&D through collaboration between industry, researchers and the NHS. It… Read More

#News

Human liver
#Cell Science #Drug discovery #New approach methodologies (NAMs) #Organoids #Preclinical development

Download the Factsheet: MASLD research needs better liver models

A new resource is now available to download for free. MASLD drug development is limited by models that don’t reflect human liver biology. HUB’s patient-derived liver organoids retain donor genetics, architecture and physiology. Download the Factsheet to learn: How organoids recapitulate steatosis and fibrosis Which readouts support target validation… Read More

#News

#3D cell culture #Assays #Organoids #Promega

From monolayer to microtissue: Measuring what matters in 3D drug discovery

Darren Heywood, Senior Product Manager at Promega UK, examines assay formats built specifically for 3D measurements. A 3D microtissue, such as a spheroid or organoid, is not a monolayer with more cells. These are three-dimensional cultures that self-organise into structures resembling real tissue. In a spheroid, as it grows, oxygen and… Read More

#Exclusive Content

TARGA imager
#Neurodevelopmental disorders #Organoids #Schizophrenia

Neurodevelopmental imaging in schizophrenia 

This paid-for advertorial by Lumencor appeared in DDW Volume 27 – Issue 3, Summer 2026. Studying neurodevelopmental disorders like schizophrenia is limited by model complexity and tissue access. Advanced stem cell models combined with high-speed imaging now enable scalable insight into neuronal activity and network behaviour.  Understanding neurodevelopment in schizophrenia remains a major… Read More

#Exclusive Content

Organoid
#3D cell culture #Drug discovery #New approach methodologies (NAMs) #Oncology #Organoids

Why traceability will make or break the organoid revolution 

By Carolina Lucchesi, Principal Scientist and Head of Microphysiological Systems, ATCC.  Across the world, regulators are sending a consistent signal: the era of animal-only preclinical testing is drawing to a close. In the United States, the Food and Drug Administration (FDA) has committed to phasing out animal testing requirements1. The European Union and United Kingdom are moving in the same direction, with regulatory bodies… Read More

#Exclusive Content

HUB Organoids Fact Sheet
#Fact Sheet #Organoids

New Fact Sheet: Liver organoid platform for predictive hepatotoxicity assessment

A new Fact Sheet is now available to download from HUB Organoids (now part of Merck). Get earlier, mechanistic insight into DILI risk with HUB Organoids’ human liver organoid platform: Donor-diverse liver organoid biobank Multiparametric live-cell assay: mitochondrial dysfunction, oxidative stress, lipid dysregulation,viability Supports lead optimisation and safer candidate selection… Read More

#News

#3D modelling #Drug development #Oncology #Organoids

Rewriting the Oncology Playbook

Dr Mark Eccleston, Director of Inaphaea, discusses how patient-derived 3D models can bridge the translational divide in oncology.  Drug development is a complex, costly, and time-consuming process with a high failure rate. Effective cancer therapy development in particular, remains challenging with only 3.4% of drugs entering clinical trials between 2000 and 2015 reaching… Read More

#Exclusive Content

#Cancer research #Collaboration #Organoids

Global collaboration aims to create safer cancer therapeutics 

An international collaboration is set to evaluate chemotherapeutic toxicity in human organoids, aiming to generate safer and more effective cancer therapeutics.  iXCells Biotechnologies, a provider of human cell-based solutions and iPSC services, has announced it has joined the collaboration alongside Rosebud Biosciences, Kantify and Incite. The project will… Read More

#Cancer Research #News

#AI #Organoids #Rare diseases

Partnership set to advance organoid-based disease models  

Cell technology company iXCells Biotechnologies has partnered with Rosebud Biosciences to advance organoid-based models for rare diseases.  The partnership will set out to develop a personalised, human-based approach for predicting drug safety and informing translational decision-making in rare diseases.  iXCells will integrate Rosebud’s organoid generation and characterisation expertise into its existing iPSC solutions, enabling access to… Read More

#Business & Investment #News

Organoids
#Cancer research #Organoids

ChristianaCare launches first-of-its-kind organoid core 

US healthcare organisation ChristianaCare has launched a first-of-its-kind organoid core to personalise cancer treatment. The organoid core was unveiled at ChristianaCare’s Cawley Center for Translational Cancer Research, with a new laboratory facility in the Helen F Graham Cancer Center & Research Institute. The new facility will be used to grow… Read More

#News

#AI / data analytics / healthtech / informatics #Automation #Drug discovery #Organoids #Webinar

Webinar: Overcome organoid workflow challenges with AI

Hosted by Drug Discovery World and supported by Galatek, this webinar explores how automation and AI enable reliable, scalable models by standardising organoid workflows. Organoids have emerged as powerful in vitro models in disease modelling, drug screening, and regenerative medicine, but their complexity introduces major workflow… Read More

Webinar date:
Supported by Galatek
#News

#Cell Science #Drug discovery #Organoids #Protein #Stem cells #Vaccines

How new scientific approaches are accelerating R&D

This is the latest episode of the free DDW Narrated Podcast, called “How new scientific approaches are accelerating R&D”. The episode covers two articles written for DDW Volume 25, Issue 1, Winter 2023/24. The first article is called ‘Accelerating recombinant protein vaccine discovery’. In the… Read More

#Featured Podcasts #Podcasts

#AI / data analytics / healthtech / informatics #Automation #Drug discovery #Organoids #Webinar

Webinar: How automation and AI can standardise organoid workflows

Hosted by Drug Discovery World and supported by Galatek, this webinar explores how automation and AI enable reliable, scalable models by standardising organoid workflows. Organoids have emerged as powerful in vitro models in disease modelling, drug screening, and regenerative medicine, but their complexity introduces major workflow… Read More

Webinar date:
Supported by Galatek
#News

Robotic arm, automation
#AI / data analytics / healthtech / informatics #Automation #Drug discovery #Organoids #Webinar

Webinar: Overcome organoid workflow challenges with automation

Hosted by Drug Discovery World and supported by Galatek, this webinar explores how automation and AI enable reliable, scalable models by standardising organoid workflows. Organoids have emerged as powerful in vitro models in disease modelling, drug screening, and regenerative medicine, but their complexity introduces major workflow… Read More

Webinar date:
Supported by Galatek
#News

Lab automation
#AI / data analytics / healthtech / informatics #Automation #Drug discovery #Organoids #Webinar

Webinar: AI-driven solutions streamline organoid workflows

Hosted by Drug Discovery World and supported by Galatek, this webinar explores how automation and AI enable reliable, scalable models by standardising organoid workflows. Organoids have emerged as powerful in vitro models in disease modelling, drug screening, and regenerative medicine, but their complexity introduces major workflow… Read More

Webinar date:
Supported by Galatek
#News